Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Arpino · SciRah

Researcher profile · Semantic Scholar

G. Arpino

Share profile

G. Arpino — researcher profile on SciRah

h-index: 46
Works: 315
Citations: 10K

Most-cited papers

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
Andrea D'Arienzo, Annarita Verrazzo, M. Pagliuca, F. Napolitano +9 more
2023EClinicalMedicine103 citations Open access
Semantic Scholar
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome.
L. Cucciniello, G. Garufi, Rossana Di Rienzo, C. Martinelli +7 more
2023Cancer Treatment Reviews62 citations Open access
Semantic Scholar
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study.
L. Provenzano, M. Dieci, G. Curigliano, M. Giuliano +33 more
2025Annals of Oncology40 citations Open access
Semantic Scholar
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.
F. Schettini, S. Nucera, T. Pascual, O. Martínez-Sáez +17 more
2024Cancer Treatment Reviews25 citations Open access
Semantic Scholar
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
E. Blondeaux, L. Boni, G. Chilà, A. Dri +15 more
2025ESMO Open17 citations Open access
Semantic Scholar
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study.
C. Molinelli, M. Bruzzone, E. Blondeaux, T. Ruelle +15 more
2024European Journal of Cancer15 citations Open access
Semantic Scholar
Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review
Luca Scafuri, C. Buonerba, Oriana Strianese, E. de Azambuja +8 more
2025Nutrients13 citations Open access
Semantic Scholar
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients
E. Giordani, M. Allegretti, A. Sinibaldi, F. Michelotti +16 more
2024Journal of experimental & clinical cancer research : CR13 citations Open access
Semantic Scholar
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type
R. Buonaiuto, G. Neola, A. Caltavituro, Alessandra Longobardi +11 more
2024Frontiers in Oncology11 citations Open access
Semantic Scholar
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis
R. Buonaiuto, M. Fordellone, A. Caltavituro, M. Cataldo +18 more
2025EClinicalMedicine9 citations Open access
Semantic Scholar
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review
G. Di Grazia, Arianna Dri, Angela Grieco, C. Martinelli +10 more
2025Cancers9 citations Open access
Semantic Scholar
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients
A. Gravina, P. Gargiulo, M. de Laurentiis, L. Arenare +23 more
2025ESMO Open9 citations Open access
Semantic Scholar
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients
F. Miglietta, L. Pontolillo, C. de Angelis, R. Caputo +15 more
2024Breast9 citations Open access
Semantic Scholar
Prognostic implications of risk definitions from the monarchE and NATALEE trials
L. Arecco, E. Blondeaux, M. Bruzzone, G. Arpino +16 more
2025Journal of the National Cancer Institute8 citations Open access
Semantic Scholar
Cardio-Oncology Challenges in Elderly Patients
Ester Topa, E. de Rosa, A. Cuomo, Francesco Curcio +26 more
2025Journal of Clinical Medicine7 citations Open access
Semantic Scholar
Adipocyte-derived extracellular vesicles sustain mitochondrial metabolism in breast cancer cells: New insights into the cross-talk between cancer cells and the tumor microenvironment
L. Gelsomino, Piercarlo Del Console, Maria Stella Murfuni, M. Gaspari +11 more
2025International Journal of Oncology7 citations Open access
Semantic Scholar
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): an Italian Delphi consensus report.
F. Miglietta, M. Razeti, A. Caltavituro, Arianna Dri +31 more
2025Critical reviews in oncology/hematology6 citations Open access
Semantic Scholar
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review.
A. Zambelli, L. Cortesi, M. Gaudio, G. Arpino +25 more
2024Cancer Treatment Reviews6 citations Open access
Semantic Scholar
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
F. Poggio, E. Blondeaux, M. Tagliamento, M. Perachino +26 more
2024ESMO Open6 citations
Semantic Scholar
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
L. Cucciniello, E. Blondeaux, C. Bighin, Simona Gasparro +16 more
2024npj Breast Cancer5 citations Open access
Semantic Scholar
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review
E. Pietroluongo, Angelo Luciano, Annarita Peddio, R. Buonaiuto +10 more
2024Journal of Medical Virology5 citations Open access
Semantic Scholar
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
R. Buonaiuto, A. Caltavituro, M. Tafuro, Alessandra Longobardi +10 more
2024Breast5 citations Open access
Semantic Scholar
Management of trastuzumab deruxtecan-related adverse events in breast cancer: Italian expert panel recommendations
G. Bianchini, A. Fabi, V. Guarneri, G. Arpino +6 more
2025Future Oncology4 citations Open access
Semantic Scholar
Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.
R. Buonaiuto, F. Martorana, P. Marino, F. Mangiacotti +12 more
2025European Journal of Cancer4 citations
Semantic Scholar
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study.
P. De Placido, Rossana Di Rienzo, E. Pietroluongo, C. Martinelli +22 more
2025European Journal of Cancer4 citations Open access
Semantic Scholar
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan
A. A. Valsecchi, S. Pisegna, Andrea Antonuzzo, G. Arpino +10 more
2025The Oncologist4 citations Open access
Semantic Scholar
Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions.
A. Caltavituro, R. Buonaiuto, Fabio Salomone, Giovanna Pecoraro +9 more
2024Critical reviews in oncology/hematology4 citations Open access
Semantic Scholar
Abstract GS1-03: Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: An exploratory analysis from the ALTTO (BIG 2-06) trial
M. Lambertini, F. Samy, E. Agostinetto, L. Arecco +15 more
2026Clinical Cancer Research3 citations
Semantic Scholar
Abstract GS3-02: Fertility and ovarian function preservation in premenopausal women with early breast cancer: results from the multicenter prospective PREgnancy and FERtility (PREFER) study
M. Lambertini, E. Blondeaux, V. Fontana, S. Cinieri +28 more
2026Clinical Cancer Research3 citations
Semantic Scholar
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
G. Mazzoli, L. Provenzano, M. Dieci, G. Curigliano +38 more
2026Breast2 citations Open access
Semantic Scholar
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus
C. de Angelis, D. de Biase, L. Gerratana, G. Arpino +12 more
2026Breast2 citations Open access
Semantic Scholar
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
G. Bianchini, L. Malorni, R. Caputo, A. Zambelli +24 more
2026Clinical Cancer Research2 citations Open access
Semantic Scholar
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA Study
M. Cazzaniga, P. Pronzato, D. Amoroso, G. Arpino +33 more
2025Cancers2 citations Open access
Semantic Scholar
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy
S. Pizzamiglio, A. Blanda, V. Appierto, P. Minicozzi +17 more
2025npj Breast Cancer2 citations Open access
Semantic Scholar
52P Dynamics of ctDNA and serum thymidine kinase activity in patients with ER+/HER2- metastatic breast cancer receiving abemaciclib vs palbociclib or ribociclib: Early results of the TIRESIAS trial
G. Anichini, F. Galardi, C. Biagioni, M. Paoli +16 more
2025ESMO Open2 citations Open access
Semantic Scholar
323MO Efficacy of adjuvant anti-PD-L1 avelumab by tumor infiltrating lymphocytes (TILs) for high-risk triple-negative breast cancer in the phase III A-BRAVE trial
M. Dieci, G. Bisagni, L. Nicolé, P. Schmid +16 more
2025Annals of Oncology2 citations Open access
Semantic Scholar
COVID-19 in patients with thymic epithelial tumors with or without Good’s syndrome: a single-center retrospective study
E. Pietroluongo, Annarita Peddio, P. De Placido, M. Tortora +22 more
2024BMC Cancer2 citations Open access
Semantic Scholar
Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials
R. Buonaiuto, F. Mangiacotti, Fabiola Giudici, M. Tafuro +12 more
2026Breast1 citations Open access
Semantic Scholar
Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis
R. Caputo, G. Buono, C. Martinelli, A. Botticelli +26 more
2026ESMO Open1 citations Open access
Semantic Scholar
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
F. Ligorio, L. Provenzano, G. Fotia, M. Dieci +74 more
2026Breast1 citations Open access
Semantic Scholar
Abstract P4-11-08: Comparative analysis of clinician and AI decision making in HR+/HER2- early breast cancer
R. Buonaiuto, A. Caltavituro, Rossana Di Rienzo, Angela Grieco +12 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis
F. Schettini, S. Nucera, G. Di Grazia, Fabiola Giudici +17 more
2025JNCI Cancer Spectrum1 citations Open access
Semantic Scholar
Multidisciplinary discussion on phenotypical characterization of metastatic breast cancer and patient pathway optimization from an expert panel across South Italian regions
Raffaele Ardito, G. Arpino, R. Caputo, M. Ciccarese +8 more
2025Scientific Reports1 citations Open access
Semantic Scholar
Abstract PO4-03-07: The impact of chemotherapy relative dose intensity on pathological complete response in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
R. Buonaiuto, G. Neola, A. Caltavituro, P. Trasacco +10 more
2024Cancer Research1 citations
Semantic Scholar
Abstract PO4-04-05: HER2 immunohistochemistry (IHC) expression in HER2-positive (HER2-pos) metastatic breast cancer (mBC): clinical and prognostic differences between IHC 2+ and IHC 3+ populations
Arianna Dri, E. Blondeaux, C. Bighin, Simona Gasparro +16 more
2024Cancer Research1 citations
Semantic Scholar
Measurement of resting energy expenditure and its accuracy in women with breast cancer.
I. Cioffi, O. Di Vincenzo, D. Morlino, Bruna Ramos da Silva +8 more
2024Clinical Nutrition1 citations Open access
Semantic Scholar
Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy
Luca Scafuri, C. Buonerba, V. di Lauro, Vincenzo Tortora +12 more
2024Oncology and Therapy1 citations Open access
Semantic Scholar
148P The impact of chemotherapy relative dose intensity on pathological complete response and event-free survival in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy
R. Buonaiuto, F. Martorana, P. Marino, A. Caltavituro +16 more
2024ESMO Open1 citations Open access
Semantic Scholar
Corrigendum to "Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)" [Cancer Treatment Reviews 123 (2024) 102672].
Arianna Dri, G. Arpino, G. Bianchini, G. Curigliano +11 more
2024Cancer Treatment Reviews1 citations
Semantic Scholar
Optimizing early identification and management of trastuzumab deruxtecan-related interstitial lung disease: insights from a multidisciplinary expert panel
L. Licata, C. Lisanti, G. Arpino, L. Cereser +7 more
2026Frontiers in Oncology0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Del Mastro×26
Invite
L. Del Mastro — researcher profile on SciRah
M. Giuliano×21
Invite
M. Giuliano — researcher profile on SciRah
F. Puglisi×20
Invite
F. Puglisi — researcher profile on SciRah
C. de Angelis×18
Invite
C. de Angelis — researcher profile on SciRah

M. de Laurentiis

×17

Invite

M. de Laurentiis — researcher profile on SciRah

Invite

A. Fabi — researcher profile on SciRah

A. Caltavituro×13

Invite

A. Caltavituro — researcher profile on SciRah

R. Buonaiuto×10

Invite

R. Buonaiuto — researcher profile on SciRah

Invite

A. Gennari — researcher profile on SciRah

G. Bianchini×9

Invite

G. Bianchini — researcher profile on SciRah

Invite

R. Caputo — researcher profile on SciRah

F. Montemurro×7

Invite

F. Montemurro — researcher profile on SciRah